Background: Patients with obstructive sleep apnea syndrome (OSAS) have an increased risk of cardiovascular events including myocardial infarction and stroke. Objective: To determine whether in vivo platelet activation and the generation of procoagulant platelet-derived microparticles (PMP) are increased during sleep in patients with OSAS. Methods: In vivo platelet activation and PMP formation was determined using flow cytometry in 12 patients with untreated OSAS during and after sleep (4 and 7 a.m.). To study the effect of treatment with continuous positive airway pressure (CPAP), the measurements were repeated at the same time points after initiation of CPAP therapy. Healthy volunteers served as controls (n = 6). Results: Patients with OSAS had an increased percentage of platelets positive for the activation-dependent epitopes CD63 and CD62P during sleep (4 a.m.) compared to controls (4.8 ± 0.8 vs. 1.9 ± 0.4% for CD63, p < 0.01, and 2.0 ± 0.5 vs. 1.1 ± 0.3% for CD62P, p < 0.05). In OSAS patients, the amount of CD63- and CD62P-positive platelets was significantly elevated at 4 compared to 7 a.m. (4.8 ± 0.8 vs. 2.6 ± 0.4% for CD63 and 2.0 ± 0.5 vs. 1.1 ± 0.2% for CD62P, p < 0.05), but not in the control group. The levels of PMP were similar in patients with OSAS and controls at 4 and 7 a.m. After 1 night of CPAP therapy, there was a trend to reduced levels of CD63- and CD62P-positive platelets at 4 a.m. Conclusions: Patients with OSAS have increased in vivo platelet activation during sleep, which may contribute to the increased incidence of cardiovascular events in patients with OSAS.

Keywords:
Cardiovascular events, Obstructive sleep apnea syndrome, Platelet activation, Platelet-derived microparticles, Stroke
1.
Partinen M, Jamieson A, Guilleminault C: Long-term outcome for obstructive sleep apnea syndrome patients: Mortality. Chest 1988;94:1200–1204.
2.
Hung J, Whitford EG, Parsons RW, Hillmann DR: Association of sleep apnea with myocardial infarction in men. Lancet 1990;336:261–264.
3.
Bassetti C, Aldrich MS: Sleep apnea in acute cerebrovascular diseases. Final report on 128 patients. Sleep 1999;22:217–223.
4.
Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH: Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990;82:897–902.
5.
Elliott WJ: Circadian variation in the timing of stroke onset: A meta-analysis. Stroke 1998;29:992–996.
6.
Bassetti C, Aldrich M: Night time versus daytime transient ischaemic attack and ischaemic stroke: A prospective study of 110 patients. J Neurol Neurosurg Psychiatry 1999;67:463–467.
7.
Koskenvuo M, Kaprio J, Telakivi T, Partinen M, Heikkilae K, Sarna S: Snoring as a risk factor for ischemic heart disease and stroke in men. Br Med J 1987;294:16–19.
8.
Palomaeki H, Partinene M, Juvela S, Kaste M: Snoring as a risk factor for sleep-related brain infarction. Stroke 1989;20:1311–1315.
9.
Bokinsky G, Miller M, Ault K, Husband P, Mitchell J: Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. Chest 1995;108:625–630.
10.
Tofler GH, Brezinski MB, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE: Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514–1518.
11.
Mann KG: Membrane-bound enzyme complexes in blood coagulation; in Progress of Hemostasis and Thrombosis. New York, Grune & Stratton, 1984, pp 1–23.
12.
Lee YJ, Jy W, Horstmann LL, Janania J, Reyes Y, Kelley RE, Ahn YS: Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993;72:295–304.
13.
Geiser T, Sturzenegger M, Genewein U, Haeberli A, Beer JH: Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 1998;29:1770–1777.
14.
Gugger M: Comparison of ResMed AutoSet (version 3.03) with polysomnography in the diagnosis of the sleep apnoea/hypopnoea syndrome. Eur Resp J 1997;10:587–591.
15.
Genewein U, Haeberli A, Straub PW, Beer JH: Rebound after cessation of oral anticoagulant therapy: The biochemical evidence. Br J Hematol 1996;92:479–485.
16.
Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691–3699.
17.
Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667–689.
18.
Carlson J, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin G: Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993;102:1763–1768.
19.
Jennum P, Wildschiodtz G, Juel Christensen N, Schwartz T: Blood pressure, catecholamines and pancreatic polypeptide in obstructive sleep apnea with and without nasal continuous positive airway pressure (nCPAP) treatment. Am J Hypertens 1989;2:847–852.
20.
Eisensehr I, Ehrenberg BL, Noachtar S, Korbett K, Byrne A, McAuley A, Palabrica T: Platelet activation, epinephrine, and blood pressure in obstructive sleep apnea syndrome. Neurology 1998;51:188–195.
21.
Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W: Platelet function in patients with obstructive sleep apnea syndrome. Eur Respir J 2000;16:648–652.
22.
McKenzie ME, Gurbel PA, Levine DJ, Serebruany VL: Clinical utility of available methods for determining platelet function. Cardiology 1999;92:240–247.
23.
Hagberg IA, Lyberg T: Blood platelet activation evaluated by flow cytometry: Optimised methods for clinical studies. Platelets 2000;11:137–150.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.